424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

10-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

S-8 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

SCHEDULE 13G/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00

Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00

Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00

Leerink Partners initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $25.00

H.C. Wainwright initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $27.00

Piper Sandler initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $21.00

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here. Details on the presentations are as follows: Title: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockadeSession Category: Experimental and Molecular TherapeuticsSession Title:

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT's selective RAS:PI3Kα breaker Preliminary clinical data from the BBO-11818 Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety, with additional data expected in the second half of 2026; interna

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company's participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare ConferencePresentation: Tuesday, March 10, 2026, at 10:00 a.m. ET. Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at h

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026. The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which wil

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025. The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $13.19 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pemb

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. A live webcast of the presentation will be accessible on the "Events" page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at least 90 days following the event. About BBOTBBOT is a clinical-stage biopharmaceutical company advancing a ne

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $12.88 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy and in combination with standard of care therapies in mutant or wild-type PIK3CA breast cancer modelsBBOT will also present a trial in progress poster on BREAKER-101, a Phase 1 clinical trial evaluating BBO-10203 in patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer with initial Phase 1 data expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar